Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ:STML) with a price target of $62, which represents a potential upside of 332% from where the stock is currently trading. The report follows the company’s third-quarter results, posting EPS of ($0.53) vs. Roth’s estimate of ($0.48) and a consensus of ($0.58). The company’s cash at the end of the quarter was $65 million, sufficient to fund operations for the next two years, according to the analyst.
Pantginis wrote, “While it has been quiet on the STML front, we believe the company’s visibility should increase soon with abstracts primed for the SNO and ASH conferences and more significantly, expected data from its two ongoing open-label studies of SL-401 in BPDCN and AML and SL-701 in GBM.” The analyst continued, “In the short term, we are now looking forward to updates at SNO from the SL-701 study in GBM, data at ASH from preclinical studies in SL-401 in IL-3R+ cancers (that will support trial initiations in other IL-3R+ tumor types), SL-501 preclinical data in Hodgkin’s and NHL and SL-101 preclinical data in AML. Beyond that, we anticipate updates from the company regarding the ongoing open-label studies and believe the current valuation is compelling.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -4.0% and a 45.4% success rate. Pantginis has a -5.5% average return when recommending STML, and is ranked #3261 out of 3369 analysts.